Abstract
Purpose: :
The purpose of this study is comparing the one year results of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with intravitreal triamcinolone (IVTA) and PDT for retinal angiomatous proliferation (RAP) patients.
Methods: :
We retrospectively reviewed 11 eyes treated with IVB plus PDT and 12 eyes treated with IVTA plus PDT. All patients (21 patients; 11 men, 10 women) were performed without prior treatment and were followed at least 12 months. For this study using bevacizumab was approved by the Institutional Review Board/Ethics Committee at Fukushima Medical University and Kagawa University. PDT was performed one or two days after IVB (1.25mg/0.05ml) and seven days after IVTA (4mg/0.1ml).
Results: :
The mean logMAR best-corrected visual acuity (BCVA) at baseline and 12 months were 0.54 and 0.36 in the IVB plus PDT group, 0.54 and 0.87 in the IVTA plus PDT group, respectively. At 12 months after treatment, the mean BCVA significantly improved by IVB plus PDT (p<0.05) and declined by IVTA plus PDT (p<0.05). The mean change in BCVA at 12 months from baseline was an improvement of 1.9 lines by IVB plus PDT and a decline of 3.3 lines by IVTA plus PDT. Visual acuity at 12 months compared with baseline improved in 6 eyes (55%, improved by≥3 lines), remained in 5 eyes (45%) in the IVB plus PDT group and improved in 2 eyes (17%), remained in 7 eyes (58%), declined in 3 eyes (25%, declined by≤3 lines) in the IVTA plus PDT group. At 12 months, there was no leakage from RAP lesion in all 11 eyes in the IVB plus PDT group, in 8 of 12 eyes (67%) in the IVTA plus PDT group. There were no complications such as severe vision loss, endophthalmitis and systemic events.
Conclusions: :
IVB plus PDT for RAP more effectively maintained or improved VA and reduced or eliminated leakage from RAP lesion than IVTA plus PDT.
Keywords: age-related macular degeneration • photodynamic therapy • vascular endothelial growth factor